Skip to main content
search here
username password
Macmillan and Cancerbackup merged in 2008. Together we provide free, high quality information for people affected by cancer through our publications, website and phone service. Find out more| .
How we produce our information|
This information is about a treatment for cancer called ADEPT (Antibody-Directed Enzyme Prodrug Therapy), which is in development. It aims to give a balanced summary of the information available so far. You may want to discuss the information with a nurse or doctor at the hospital where you are having treatment.
When a drug is being developed, it has to go through various stages of research called clinical trials| or studies. The aim of these is to establish a safe dosage, the side effects that the drug may cause and which cancers it may be used to treat. The trials also find out how effective the drug is, whether it is better than the existing treatments, or whether it has extra benefits when given with existing drugs.
Many drugs that are thought to be promising may be found not to be as good as existing treatments, or to have side effects that outweigh any benefits. For this reason, doctors and other medical staff carry out frequent and careful checks on the progress of everyone who is taking one of these developmental drugs. If you are having a developmental drug, your doctor will explain all about the drug, the procedures being used, and how you will be looked after while you are taking it. If you have concerns at any time, you should ask your doctor or nurse for information and advice.
ADEPT is a new type of cancer treatment that uses drugs called monoclonal antibodies. At the moment, ADEPT is being used only in clinical trials. The trials aim to find out whether ADEPT may be useful as a new type of treatment for bowel cancer .
Monoclonal antibodies| recognise certain proteins that are found on the surface of some cancer cells. They are used to try to destroy the cancer cells, while causing little harm to normal cells. The monoclonal antibody recognises the protein on the surface of the cancer cell and locks onto it. Some monoclonal antibodies can then trigger the body’s immune system to attack the cancer cells and can also cause the cells to destroy themselves. Sometimes (when used in cancer treatment) monoclonal antibodies have a cancer drug or radioactive substance attached to them. They can be used in this way to deliver treatment directly to the cancer cell. This is known as targeted therapy.
ADEPT is a type of targeted therapy. It uses a monoclonal antibody to carry an enzyme directly to the cancer cells. Enzymes are proteins that control chemical reactions in the body. First, the monoclonal antibody is given (with the enzyme attached). A few hours later, a second drug (the pro-drug) is given. When the pro-drug comes into contact with the enzyme, a reaction takes place. This reaction activates the pro-drug and it's then able to destroy the cancer cells. As the enzyme does not attach to normal cells, this treatment does not affect them.
ADEPT is a colourless fluid.
ADEPT is given by a drip (infusion) through a small tube (cannula) inserted into a vein. The monoclonal antibody and the pro-drug are usually given in two separate doses on the same day.
Trials are looking at the side effects that may occur. As ADEPT is still a relatively new treatment, it's too early to know all of the possible side effects. However, the following appear to be the most common:
If you have any questions about these or any other side effects, talk to your doctor or nurse. It is also important to let them know if you have any symptoms or side effects that you think may be related to the treatment.
This information has been compiled using information from a number of reliable sources including:
DeVita,V et al. Cancer - Principles & Practice of Oncology. 8th Edition. 2008. Lippincott, Williams & Wilkins.
For further references, please see the general bibliography| .
Posted by bob jk
Posted by lesley22
Posted by Dianne J
If you have any questions about cancer, need support or just want someone to talk to, ask Macmillan.
Browser does not support script.